Company Declares Non-Reliance on Past Financials, Citing Material Errors and Weaknesses
summarizeSummary
PreAxia Health Care Payment Systems Inc. has declared that its financial statements for the three months ended August 31, 2025, should no longer be relied upon due to material errors, and will continue to report a material weakness in internal controls.
check_boxKey Events
-
Non-Reliance on Financial Statements Declared
Management has determined that previously issued financial statements for the three months ended August 31, 2025, should no longer be relied upon due to material errors in stock award valuation, timing, and lack of option disclosures.
-
Material Financial Restatement Expected
The company expects to restate the affected financial information in an amended Form 10-Q, as the impact of the errors is considered material to the financial statements for the Non-Reliance Period.
-
Continued Material Weakness in Internal Controls
The company will continue to report a material weakness in its internal control over financial reporting and disclosure controls and procedures, concluding they were not effective for the non-reliance periods.
auto_awesomeAnalysis
This filing signals significant issues with the company's financial reporting and internal controls. The declaration of non-reliance on previously issued financial statements for the three months ended August 31, 2025, due to material errors in stock award valuation and option disclosures, severely impacts investor confidence in the accuracy of past reported results. Furthermore, the continued reporting of a material weakness in internal control over financial reporting indicates a systemic issue that could lead to further misstatements. Investors should exercise extreme caution as the reliability of financial data is compromised, and the company faces the task of restating financials and addressing control deficiencies.
At the time of this filing, PAXH was trading at $0.22 on OTC in the Trade & Services sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.01 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.